Hanmi Hits Jackpot Again, This Time With Janssen

Hanmi's run of major licensing out deals is continuing apace. Just a few days after announcing a huge diabetes licensing agreement with Sanofi, the South Korean pharma firm has landed another global pact worth up to $915m for its long-acting GLP/GCG analog for diabetes and obesity, this time with Janssen.

SEOUL - Hanmi Pharmaceutical Co. Ltd. has inked a licensing out agreement with Janssen Pharmaceutical Cos. for the development and commercialization of its diabetes and obesity therapy HM12525A, a long-acting GLP/GCG analog.

Following a string of major licensing out deals with multinationals this year, the agreement will bring further international recognition of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By 

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?